Plan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s pushnews2026-04-10T19:00:33+00:00April 10th, 2026|Endpoints News|
AbbVie suggests new interpretation of ‘patient’ is necessary in 340B lawsuitnews2026-04-09T18:18:32+00:00April 9th, 2026|Endpoints News|
DOJ weighs in favor of pharma on 340B disputenews2026-04-02T17:49:02+00:00April 2nd, 2026|Endpoints News|
Sanofi, AbbVie, Novartis and AstraZeneca face revived 340B pricing casenews2026-03-18T19:34:40+00:00March 18th, 2026|Endpoints News|
Federal judge halts CDC’s childhood vaccine overhaul news2026-03-16T20:37:18+00:00March 16th, 2026|Endpoints News|
Moderna will pay $950M to settle Covid vaccine patent claims with Arbutus, Roivantnews2026-03-03T22:30:30+00:00March 3rd, 2026|Endpoints News|
DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case news2026-02-26T20:42:26+00:00February 26th, 2026|Endpoints News|
States sue Kennedy over US childhood vaccine overhaulnews2026-02-25T14:57:13+00:00February 25th, 2026|Endpoints News|
AbbVie, PhRMA can proceed with 340B case in Hawaiinews2026-02-19T19:35:39+00:00February 19th, 2026|Endpoints News|
Moderna faces setback in Arbutus’ mRNA patent fightnews2026-02-17T20:36:05+00:00February 17th, 2026|Endpoints News|
